EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study

Guangzhong Guo iD, Ziyue Zhang, Jiubing Zhang iD, Dayang Wang, Sensen Xu iD, Shuang Wu iD, Kaiyuan Deng, Yage Bu, Zhiyuan Sheng, Jinliang Yu iD, Yushuai Gao, Zhaoyue Yan und 4 weitere

Cancer Medicine · 2025-03 · 14 (5)

DOI: 10.1002/cam4.70733 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2025-03. Verfasst von Guangzhong Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Juha International Center for Neurosurgery, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasm Recurrence, Local, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Research Foundation of the Health Commission of Henan Province, Natural Science Foundation of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma.

Methods

We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis.

Results

Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM.

Conclusions

In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasm Recurrence, LocalGliomaBrain NeoplasmsBiomarkers, TumorHumansFemaleMaleMiddle AgedProspective StudiesMutationAdultPrognosisAged

Stichwörter der Autor:innen

biomarkercirculating tumor DNAclonal evolutiongliomarisk stratificationtumor recurrence

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Juha International Center for Neurosurgery, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
  • Department of Pathology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Department of Radiology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Henan Provincial Neurointerventional Engineering Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Henan Engineering Research Center of Cerebrovascular Intervention Innovation, Zhengzhou,…
  • Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.

ORCID-Profile: Guangzhong Guo, Jiubing Zhang, Sensen Xu, Shuang Wu, Jinliang Yu, Xingyao Bu

Förderung

  • the Research Foundation of the Health Commission of Henan Province
  • Natural Science Foundation of Henan Province

Zitieren

APA

Guo, G., Zhang, Z., Zhang, J., Wang, D., Xu, S., Wu, S., Deng, K., Bu, Y., Sheng, Z., Yu, J., Gao, Y., Yan, Z., Zhao, R., Wang, M., Li, T., & Bu, X. (2025). Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study. Cancer Medicine, 14(5). https://doi.org/10.1002/cam4.70733

Vancouver

Guo G, Zhang Z, Zhang J, Wang D, Xu S, Wu S, et al. Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study. Cancer Medicine. 2025;14(5). doi:10.1002/cam4.70733

BibTeX
@article{Guo2025,
  author = {Guo, Guangzhong and Zhang, Ziyue and Zhang, Jiubing and Wang, Dayang and Xu, Sensen and Wu, Shuang and Deng, Kaiyuan and Bu, Yage and Sheng, Zhiyuan and Yu, Jinliang and Gao, Yushuai and Yan, Zhaoyue and Zhao, Ruijiao and Wang, Meiyun and Li, Tianxiao and Bu, Xingyao},
  title = {Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {5},
  doi = {10.1002/cam4.70733}
}
Kostenlos starten →